

Title	Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1
Author(s)	Hasegawa, Tetsuo; Kikuta, Junichi; Sudo, Takao et al.
Citation	Nature Immunology. 2019, 20(12), p. 1631–1643
Version Type	АМ
URL	https://hdl.handle.net/11094/93182
rights	© 2019, The Author(s), under exclusive licence to Springer Nature America, Inc.
Note	

The University of Osaka Institutional Knowledge Archive : OUKA

https://ir.library.osaka-u.ac.jp/

The University of Osaka

1 Title

2 Identification of a novel arthritis-associated osteoclast precursor macrophage

3 regulated by FoxM1

4

5 Authors

⁶ Tetsuo Hasegawa^{1,2}, Junichi Kikuta^{1,3}, Takao Sudo¹, Yoshinobu Matsuura¹,

⁷ Takahiro Matsui¹, Szandor Simmons¹, Kosuke Ebina⁴, Makoto Hirao⁴, Daisuke

⁸ Okuzaki⁵, Yuichi Yoshida⁶, Atsushi Hirao⁷, Vladimir V. Kalinichenko⁸, Kunihiro

9 Yamaoka², Tsutomu Takeuchi², Masaru Ishii^{1,3*}

10

11 Affiliations

¹² ¹Department of Immunology and Cell Biology, Graduate School of Medicine and

13 Frontier Biosciences, Osaka University, Osaka, Japan

¹⁴ ²Division of Rheumatology, Department of Internal Medicine, Keio University

- 15 School of Medicine, Tokyo, Japan
- ¹⁶ ³WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan

1	⁴ Department of Orthopaedic Surgery, Osaka University, Osaka, Japan
2	⁵ Genome Information Research Center, Research Institute for Microbial
3	Diseases, Osaka University, Osaka, Japan
4	⁶ Department of Gastroenterology and Hepatology, Osaka University, Osaka,
5	Japan
6	⁷ Division of Molecular Genetics, Cancer Research Institute, WPI Nano Life
7	Science Institute (WPI-Nano LSI), Kanazawa University, Kanazawa, Japan
8	⁸ Center for Lung Regenerative Medicine, Division of Pulmonary Biology,
9	Cincinnati Children's Hospital Medical Center, Cincinnati, USA
9 10	Cincinnati Children's Hospital Medical Center, Cincinnati, USA
9 10 11	Cincinnati Children's Hospital Medical Center, Cincinnati, USA Correspondence to
9 10 11 12	Cincinnati Children's Hospital Medical Center, Cincinnati, USA Correspondence to Masaru Ishii, Department of Immunology and Cell Biology, Osaka University
9 10 11 12 13	Cincinnati Children's Hospital Medical Center, Cincinnati, USA Correspondence to Masaru Ishii, Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine and Frontier Biosciences, 2-2 Yamada-oka, Suita,
9 10 11 12 13 14	Cincinnati Children's Hospital Medical Center, Cincinnati, USA Correspondence to Masaru Ishii, Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine and Frontier Biosciences, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
9 10 11 12 13 14	Cincinnati Children's Hospital Medical Center, Cincinnati, USA Correspondence to Masaru Ishii, Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine and Frontier Biosciences, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan Email: mishii@icb.med.osaka-u.ac.jp

1 Abstract

Osteoclasts have a unique bone-destroying capacity, playing key roles in 2 steady-state bone remodelling and arthritic bone erosion. Whether these two 3 populations of osteoclasts in different tissue settings arise from the same 4 precursor states of monocytoid cells is presently unknown. Here, we show that 5 osteoclasts in pannus originate exclusively from circulating bone marrow-derived 6 locally resident macrophages. 7 cells and not from We identify 8 CX₃CR1^{hi}Ly6C^{int}F4/80⁺I-A/I-E⁺ macrophages (termed "arthritis-associated osteoclastogenic macrophages [AtoMs]") as the osteoclast 9 precursor (OP)-containing population in the inflamed synovium, comprising a subset 10 conventional homeostatic 11 distinct from OPs in bone remodelling. Tamoxifen-inducible FoxM1 deletion suppressed the capacity of AtoMs to 12 differentiate into osteoclasts in vitro and in vivo. Furthermore, synovial samples 13 from human rheumatoid arthritis (RA) patients contained 14 CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD80⁻CD86⁺ cells that corresponded to human 15 AtoMs, and osteoclastogenesis was inhibited by the FoxM1 inhibitor, 16

1 thiostrepton, constituting a potential target for RA treatment.

2

3 Introduction

Macrophages comprise a variety of subsets with diverse biological activities, 4 contributing to tissue homeostasis and a broad spectrum of pathogenesis¹⁻⁴. In 5 response to environmental cues, they follow distinct developmental pathways, 6 such as differentiation into osteoclasts. Osteoclasts are myeloid lineage cells 7 with unique bone-destroying capacity and require macrophage-colony 8 stimulating factor (M-CSF) and receptor activator of NF-kB ligand (RANKL) for 9 differentiation and survival^{5,6}. They play a key role in maintaining skeletal 10 homeostasis by supporting steady-state bone remodelling in the bone marrow 11 (BM). However, in contrast to this physiological role, osteoclasts are also 12 involved in pathological arthritic bone erosion in patients with rheumatoid arthritis 13 (RA), which occurs where the hypertrophied synovium⁷ (called "pannus") 14 invades the outer surface of the articular bone⁶. Previous studies have 15 determined that the Ly6C^{hi} monocytic population in the BM contains osteoclast 16

precursors (OPs) in arthritic mice^{8,9}, and a recent study demonstrated that 1 CX₃CR1 could be a marker for osteoclasts differentiated from BM-derived 2 dendritic cells in inflammatory conditions¹⁰. Nevertheless, a precise analysis of 3 OPs has not yet been performed in "inflamed synovium", the actual site of bone 4 erosion in arthritis, mainly due to technical difficulties associated with 5 approaching and isolating tiny synovial tissues on the so-called "bare area"¹¹, 6 where bone is exposed to synovium without a cartilage covering and, therefore, 7 vulnerable to erosion. It remains unknown whether the two osteoclast 8 populations in the BM and synovial tissue settings share similar differentiation 9 pathways and arise from similar precursor states of monocytoid cells¹². In 10 addition, while it has been suggested that osteoclasts in pannus derive from 11 blood, the empirical evidence for this relationship is lacking. 12 In this study, we have developed a new protocol to isolate the inflamed 13 area¹¹ arthritic synovium on the bare of mice and identified 14 CX₃CR1^{hi}Ly6C^{int}F4/80⁺I-A/I-E⁺ macrophages, which 15 we termed

osteoclastogenic

macrophages

(AtoM)",

as

"arthritis-associated

16

 $\mathbf{5}$

the

1	OP-containing population in the arthritic joints, comprising a subset distinct from
2	the BM OP-containing population ^{8,9,13} . We provided a detailed assessment of
3	the differentiation trajectory of arthritic OPs, and tamoxifen-inducible FoxM1
4	deletion suppressed the capacity of AtoMs to differentiate into osteoclasts. We
5	further demonstrated that synovial samples from RA patients contained
6	CX ₃ CR1 ⁺ HLA-DR ^{hi} CD11c ⁺ CD80 ⁻ CD86 ⁺ cells with osteoclastogenic potential
7	and showed that osteoclastogenesis by these human cells was prevented by the
8	FoxM1 inhibitor, thiostrepton. Collectively, these results demonstrate that AtoMs
9	are the OP-containing population involved in articular bone erosion and that
10	FoxM1 constitutes a potential target for RA treatment.
11	
12	Results
13	Bone marrow-derived CX ₃ CR1 ⁺ cells differentiate into osteoclasts in
14	inflamed synovium.
15	To investigate the OP population in the inflamed synovium, we used a
16	well-established experimental model, collagen-induced arthritis (CIA), in DBA1/J

mice. We elaborated an original protocol to expose the inflamed synovium on 1 the bare area¹¹ of the femur by removing the patella, patellar ligaments, and 2 quadriceps femoris muscles together under a stereoscopic microscope, and 3 isolating the tissue using microscissors (Supplementary Fig. 1a, b). After 4 removal of the Achilles tendon, isolation of the inflamed ankle joint synovium 5 was possible (Supplementary Fig. 1c, d). CX₃CR1, a fractalkine receptor and 6 marker for monocyte-lineage cells including BM-OPs under homeostatic 7 8 conditions^{8,13,14}, was also able to mark OPs in the inflamed synovium *in vitro* (Fig. 1a). We then backcrossed CX₃CR1-EGFP knock-in mice and tartrate-resistant 9 acid phosphatase (TRAP)-tdTomato transgenic mice onto the DBA1/J 10 background to develop a reporter system for osteoclast differentiation in this 11 model system. Ex vivo incubation of the inflamed synovium from double 12 transgenic mice (CX₃CR1-EGFP/TRAP-tdTomato) showed that EGFP⁺ cells 13 gradually expressed tdTomato and underwent cell fusion to differentiate into 14 osteoclasts, followed by a loss of CX₃CR1 expression (Fig. 1b and 15 Supplementary Video. 1). CX₃CR1⁺TRAP⁺ cells that were in transition from OPs 16

to osteoclasts were detected at the pannus-bone interface *in vivo* (Fig. 1c).
Together, these results suggest that EGFP⁺ cells in the synovium contain OPs
associated with arthritis.

CD11b¹⁵ As synovium-resident macrophages expressed 4 and CX₃CR1-EGFP (Supplementary Fig. 2a, b), we used BM chimeric mice with 5 CX₃CR1-EGFP/TRAP-tdTomato hematopoietic cells to determine whether 6 osteoclasts at the pannus-bone interface originate from the proliferation of local 7 CX₃CR1⁺ macrophages or newly recruited blood monocytes from BM. We used 8 a non-linear optical process, second-harmonic generation (SHG), to distinguish 9 synovial lining cells from BM cells by visualizing collagen-enriched bone 10 matrices and synovial fibrous tissues (Supplementary Fig. 2a). After confirming 11 that local EGFP⁺ macrophages were radio-resistant (Supplementary Fig. 2c-e) 12 and < 15% were replaced by BM cells 6 weeks after transplantation 13 (Supplementary Fig. 2f-h), we induced CIA in the chimeric mice (Fig. 1d). The 14 EGFP⁺ cell frequencies in the inflamed synovium were equivalent between 15 chimeric mice and control mice (Fig. 1f). In these chimeric mice, tdTomato⁺ 16

1	osteoclasts derived from the transplanted BM were detected at the pannus-
2	bone interface (Supplementary Fig. 2i). Counting the frequencies of tdTomato ⁺
3	osteoclasts among total osteoclasts labelled by TRAP staining in
4	wild-type/TRAP-tdTomato chimeras revealed that > 95% of the osteoclasts at
5	the pannus-bone interface were derived from BM (Fig. 1g). Furthermore, an
6	analysis of parabiotic mice involving wild-type and
7	CX ₃ CR1-EGFP/TRAP-tdTomato mice paired for up to 2 months showed that >
8	40% of blood CX_3CR1^+ monocytes were exchanged between parabionts,
9	although < 3% of synovial CX_3CR1^+ macrophages were exchanged under these
10	physiological conditions (Supplementary Fig. 3a-c). When CIA was induced in
11	both parabionts (Fig. 1e), EGFP ⁺ cells and tdTomato ⁺ osteoclasts were detected
12	in pannus from wild-type parabionts, supporting the idea that the CX_3CR1^+ OPs
13	and osteoclasts in pannus originated from cells in the blood circulation (Fig. 1h, i
14	and Supplementary Fig. 3d).

16 CX₃CR1^{hi}Ly6C^{int}F4/80^{hi}I-A/I-E⁺ macrophages in inflamed synovium have

1 high osteoclast differentiation potential.

To more specifically identify the subset origin of CX₃CR1⁺ OPs, we performed a 2 flow cytometric analysis of cells from the blood, BM, and synovium of CIA mice 3 one week after the onset of arthritis. The frequencies and numbers of 4 CX₃CR1^{lo}Ly6C^{hi} cells (called "inflammatory monocytes")¹⁶ were significantly 5 increased in the blood and BM of CIA mice (Fig. 2a, b). The inflamed synovium 6 of CIA mice contained CX₃CR1^{lo}Ly6C^{hi} cells, whereas CX₃CR1^{hi}Ly6C⁻ cells 7 8 (called "patrolling monocytes")¹⁶ were absent (Fig. 2c). Remarkably, there was a CX₃CR1^{hi}Ly6C^{int} subset only in the CIA synovium. Because our chimeric data 9 showed that the CX₃CR1⁺ cells were almost all derived from blood, it is likely that 10 CX₃CR1^{lo}Ly6C^{hi} cells in the blood (R1) trans-migrated into the synovium (R2) 11 and then differentiated into CX₃CR1^{hi}Ly6C^{int} cells (R3) in situ (Fig. 2d). Indeed, 12 inflamed synovium in wild-type parabionts, conjoined with CX₃CR1-EGFP mice, 13 contained R3 cells, suggesting that such cells originated from a circulating 14 population (Fig. 2e). Furthermore, when isolated R2 cells were labelled with 15 CellTrace Violet and transferred into the inflamed knee joints of wild-type mice, > 16

1	70% of the transferred R2 cells differentiated into R3 cells (Fig. 2f). These
2	results are consistent with our suggestion that R1 cells in the blood enter the
3	inflamed synovium (R2) and differentiate into R3 cells. A phenotypic analysis
4	revealed that the R3 cells were relatively large, F4/80 ^{hi} , I-A/I-E ⁺ , CD11c ^{lo} , and
5	RANK ^{dim} , and distinct from the OP-containing population in BM (BM-OPs) that
6	have been characterised as being within the CX ₃ CR1 ⁺ Ly6C ^{hi} F4/80 ⁺ fraction ^{8,13}
7	(Fig. 2g and Supplementary Fig. 4a). The R3 subset was sparse in other organs
8	under both healthy and inflamed conditions, such as dextran sulphate sodium
9	(DSS)-induced colitis (Supplementary Fig. 4b), suggesting that the R3 subset is
10	tissue-restricted in its distribution with a high abundance in the inflamed
11	synovium. Because R2 cells differentiate gradually into R3 cells in situ, both R2
12	and R3 fractions may contain transitional states. In fact, R2 and R3 cells
13	constitute heterogeneous populations at least in terms of cellular size and
14	granularity (reflected by the FSC/SSC); based on the F4/80 expression, we
15	newly defined R3' (CX ₃ CR1 ^{hi} Ly6C ^{int} F4/80 ^{hi}) as "fully differentiated R3" for further
16	analyses (Supplementary Fig. 5). Similarly, we defined R2'

1	(CX ₃ CR1 ^{lo} Ly6C ^{hi} <u>F4/80^{int}</u>) as "basal state R2". May–Giemsa staining showed that
2	the R3' cells had an abundant foamy cytoplasm and cytoplasmic vacuoles,
3	representing a macrophage morphology (Fig. 2h). In contrast, R2' cells had
4	peripherally located kidney-shaped nuclei, indicating that differentiation to the
5	macrophage state is not obligatory for monocytes after entry into the synovium
6	without an additional trigger. When stimulated directly with RANKL, R3' cells
7	readily differentiated into osteoclasts that resorbed inorganic crystalline calcium
8	phosphate in vitro (Fig. 2i), suggesting that R3' cells contain functional OPs in
9	the inflamed synovium; therefore, we designated these cells as AtoMs. The
10	proportion and osteoclastogenic potential of R3 cells were comparable in the
11	knee and ankle joints (Supplementary Fig. 6a, b). Although the BM also
12	contained a small population of CX ₃ CR1 ^{hi} Ly6C ^{int} cells with the potential to form
13	osteoclasts, May–Giemsa staining of these cells showed cells with diameters of
14	8-12 μm and peripherally located kidney-shaped nuclei (Supplementary Fig. 4c,
15	d), which is the characteristic monocyte morphology. This is explained by a
16	previous observation that CX ₃ CR1 ^{hi} Ly6C ⁻ monocytes are derived from

CX₃CR1^{Io}Ly6C^{hi} monocytes in the BM¹⁷, and CX₃CR1^{hi}Ly6C^{int} cells in the BM
 may be in transition from Ly6C^{hi} monocytes to Ly6C⁻ monocytes, indicating that
 CX₃CR1^{hi}Ly6C^{int} cells in the BM are distinct from inflamed synovium R3 cells.

4

The RANKL-RANK-OPG axis is essential for R3' cell osteoclastogenesis. 5 Previous studies reported that TNF- α and IL-6 drive osteoclast formation in 6 BM-derived macrophages (BMM) in vitro, suggesting the presence of a 7 RANKL-independent pathway of osteoclastogenesis^{18,19}. Therefore, we 8 examined whether R3' cells from the inflamed synovium can differentiate into 9 osteoclasts without RANKL. The results showed that TNF- α and IL-6 minimally 10 induced osteoclasts from R3' cells, as compared to RANKL (Fig. 3a, b). In 11 contrast, simultaneous addition of TNF- α and RANKL significantly promoted 12 RANKL-induced osteoclastogenesis (Fig. 3a, b). Previous studies showed that 13 TNF- α did not enhance osteoclastogenesis in BMM when added simultaneously 14 with RANKL. However, RANKL priming several days prior to addition of TNF- α 15 induced maximal osteoclastogenesis^{20,21}. Collectively, these results imply that 16

1	R3' cells were already primed by RANKL in the pannus microenvironment.
2	Furthermore, IL-6 was reported to trigger osteoclast formation together with
3	soluble IL-6 receptor in BM cells ²² . However, IL-6 inhibited RANKL-induced
4	osteoclastogenesis of R3' cells (Fig. 3a, b). Considering that RANKL-RANK
5	signaling is essential for osteoclastogenesis of R3' cells, we examined the effect
6	of the decoy-receptor osteoprotegerin (OPG), which showed dose-dependent
7	inhibition of osteoclastogenesis induced by RANKL or RANKL plus TNF- α (Fig.
8	3c, d).

Transcriptional profiling by RNA sequencing (RNA-Seq) identifies FoxM1 as one of the key regulators of R3' cells.

We next performed an unbiased global transcriptomic comparison of R1, R2', and R3' cells by RNA-Seq. Principal component analysis (PCA) showed tight clustering across replicates, indicating that R1–3' cells constitute distinct, reproducible subsets (Fig. 4a). Based on the top 300 upregulated genes, we found that R2' cells had higher expression levels of transcripts encoding

1	chemokines (<i>Cxcl1</i> , <i>Cxcl2</i> , <i>Ccl2</i> , <i>Ccl3</i> , and <i>Ccl4</i>), inflammatory cytokines (<i>II1</i> , <i>II6</i>
2	and Tnf), and Vegfa than R1 cells (Fig. 4b). In contrast, R3' cells showed
3	preferential expression of osteoclast marker genes (Ctsk, Acp5, Mmp9,
4	Atp6v0d2, and Ppargc1b) (Fig. 4c, d), and a gene-set enrichment analysis
5	(GSEA) showed the enrichment of genes associated with osteoclast
6	differentiation (p = 0.0123), mitochondrial translation (p < 0.0001), and oxidative
7	phosphorylation (p < 0.0001), compared to R2' cells (Fig. 4e, Supplementary Fig
8	7c, and Supplementary Table 1). To determine the transcription factors
9	responsible for regulating the osteoclastogenic potential of R3' cells, we
10	generated a global mRNA expression profile of transcription factors increased in
11	the R3' subset and predicted upstream regulators with QIAGEN's Ingenuity
12	Pathway Analysis. The predicted regulator with the top Z-score was FoxM1 ($p =$
13	$9.77E^{-19}$) (Fig. 4f and Supplementary Fig. 7d), which was increased by
14	11.69-fold; this upregulation was validated at both the mRNA and protein levels
15	(Fig. 4g, h). E2F1, which was reported previously to promote osteoclastogenesis

under inflammatory conditions²³, was detected as a predicted regulator with the
 second highest Z-score (p = 9.22E⁻²¹).

FoxM1 is a multifaceted transcription factor with diverse and cell 3 type-specific functions *in vivo*²⁴. In adult tissues, FoxM1 plays a prominent role in 4 carcinogenesis by inducing the epithelial-mesenchymal transition, a process 5 that renders tumour cells more aggressive and invasive²⁴, leading to 6 metastasis²⁵. Because the invasive phenotype of a tumour is analogous to 7 pannus in arthritis, which erodes the bone surface to destroy joints, these 8 correlations prompted us to explore the function of FoxM1 in arthritis. A natural 9 product, thiostrepton, interacts directly with FoxM1 and inhibits its binding to 10 genomic target sites²⁶. Thiostrepton also prevents FoxM1 from binding to and 11 activating its own promoter, disrupting the positive auto-regulatory loop²⁷ without 12 being cytotoxic in untransformed cells²⁸. The treatment of R3' cells with 13 thiostrepton resulted in the efficient attenuation of FoxM1 expression in a 14 dose-dependent manner (Fig. 4i) without inducing apoptosis or inhibiting cell 15 proliferation at concentrations $\leq 1 \mu M$ (Supplementary Fig. 8a, b). Thiostrepton 16

1	inhibited the osteoclastogenesis of R3' cells significantly in vitro (Fig. 4j), and
2	attenuated articular bone erosion <i>in vivo</i> (Fig. 4I, m and Supplementary Fig. 9a–
3	d). Thiostrepton partially reduced the arthritic scores of CIA mice (Fig. 4k) and
4	inhibited inflammatory cytokine expression in the synovium (Supplementary Fig.
5	8c), which may indirectly protect against bone erosion. To elucidate the effect of
6	thiostrepton on homeostatic bone remodelling, we injected 50 mg/kg
7	thiostrepton twice a week for 5 weeks. Body growth and bone morphology did
8	not differ between vehicle- and thiostrepton-treated groups, indicating that
9	thiostrepton does not affect homeostatic bone remodeling in vitro or in vivo
10	(Supplementary Fig. 8d-h). These results show that FoxM1 is involved in the
11	osteoclastogenic potential of R3' cells in arthritis.

13 Single cell RNA-sequencing analysis identifies highly osteoclastogenic

14 population in synovial R3 cells

Since only a portion of inflamed synovium cells differentiate into osteoclasts *in vivo*, we hypothesized the presence of a specific subpopulation in R3 cells,

1	which is in transition from OPs to osteoclasts on articular bone surfaces. To
2	identify and characterize the population, we sorted R3 cells from inflamed knee
3	synovium one week after CIA onset and conducted single cell RNA-sequencing
4	analysis (Fig. 5a). A total of 8,682 R3 cell transcriptomes were analyzed and
5	hierarchically clustered using t-distributed stochastic neighbor embedding
6	(t-SNE) (Fig. 5b). Among the four R3 cell clusters, P1 exhibited the
7	osteoclastogenic phenotype, constituting 10.2 % of R3 cells. The expression
8	levels of osteoclast related genes, such as Acp5 (encoding TRAP), Ctsk,
9	Atp6v0d2, Mmp9, and Itgb3 were, respectively, 56.4, 72.1, 65.3, 147, and 144
10	times higher in the P1 cluster, as compared to the rest of the cell clusters (Fig. 5c,
11	d). Chemokines, chemokine receptors, and inflammatory cytokines, such as <i>Tnf</i> ,
12	were preferentially expressed in the other clusters relative to P1 (Fig. 5c, d). The
13	expression level of <i>FoxM1</i> was 17.1 times higher in P1, as compared to the
14	other clusters, supporting its role as a regulator of osteoclastogenesis in a
15	specific cell type of the inflamed synovium (Fig. 5c, d).

1	M-CSF mediates R2 to R3 transition and upregulates FoxM1 expression
2	To identify the cytokine(s) responsible for upregulating FoxM1 expression from
3	R2 to R3 cells, we sorted R2 cells from the inflamed synovium and incubated
4	them with M-CSF and RANKL, the cytokines essential for
5	osteoclastogenesis ^{5,6,29} , or inflammatory cytokines, such as TNF- α and IL-6. The
6	results showed that M-CSF alone upregulated FoxM1 expression (Fig. 6a) and
7	triggered differentiation into R3 cells (Fig. 6b), potentially explaining the
8	protective effect of an M-CSF deletion on bone erosion in arthritis ^{30,31} . In contrast
9	RANKL, TNF- α , IL-6, and the combination of TNF- α /IL-6 had no additive effect
10	with M-CSF, and adhesion was dispensable for FoxM1 upregulation (Fig. 6a).
11	Consistent with previous studies showing that inflammatory cytokines stimulate
12	the production of M-CSF from synovial fibroblasts ³² , chondrocytes ³³ , and
13	endothelial cells ³⁴ , the M-CSF expression levels were higher in inflamed
14	synovium than in BM and healthy synovium, signifying an arthritis-specific
15	environment that could promote erosive events (Fig. 6c, d). Although
16	overexpression of FoxM1 did not induce spontaneous osteoclast formation

(Supplementary Fig. 10a-c), the minimum dose of M-CSF required for
 RANKL-induced osteoclastogenesis was lower in macrophages overexpressing
 FoxM1, supporting its role in partially replacing the contribution of M-CSF to
 osteoclastogenesis (Supplementary Fig. 10d, e).

The source of key cytokines in inflamed synovium was further examined by 5 isolating leukocytes (Lin⁺CD45⁺ cells), endothelial cells 6 (Lin⁻CD45⁻CD31⁺CD140a⁻ cells), and fibroblasts (Lin⁻CD45⁻CD140a⁺CD31⁻ 7 cells) from CIA synovium (Fig. 6e). The expression of M-CSF was higher in 8 fibroblasts and leukocytes, as compared to endothelial cells, while RANKL 9 expression in fibroblasts was about 400 times higher than in leukocytes and 10 endothelial cells (Fig. 6f). Among inflammatory cytokines, the expression of IL-6 11 was highest in fibroblasts and TNF was highest in leukocytes (Fig. 6f). 12 We next examined whether FoxM1 expression levels differ between R3 13 cells and mature osteoclasts. Approximately 40% of the R3 cells seeded on the 14 plate differentiated into osteoclasts (Supplementary Fig. 11a). Resultant 15

16 mononuclear cells and multinucleated mature osteoclasts were isolated from the

1	temperature-responsive cell cultureware, RepCell (Supplementary Fig. 11b),
2	and FSC ^{hi} SSC ^{hi} TRAP-tdtomato ⁺ multinucleated osteoclasts were sorted as
3	described previously ¹⁰ , with slight modifications (Supplementary Fig. <mark>11</mark> c).
4	FoxM1 expression was comparable between R3 cells and mature osteoclasts
5	(Supplementary Fig. 11d), indicating that multinucleation does not upregulate
6	FoxM1 expression.

8 FoxM1 contributes to arthritis-induced bone destruction

9	We next analyzed the effects of the FoxM1 time-specific deletion in
10	FoxM1 ^{fl/fl} Rosa26 ^{CreERT2} mice. Since C57BL/6 (B6) mice were resistant to reliable
11	CIA induction, we used the collagen antibody-induced arthritis (CAIA) model. We
12	found that R3' cells with high FoxM1 expression levels also developed under
13	these conditions and that arthritis was consistently induced in B6 mice ³⁵
14	(Supplementary Fig. <mark>12</mark> a–c). The <i>in vivo</i> injection of tamoxifen efficiently deleted
15	FoxM1 genes (Fig. 7a, b), and the suppression of FoxM1 expression was most
16	significant in CX ₃ CR1 ⁺ macrophages (Fig. 7c). FoxM1 deletion partially inhibited

1	synovial R3 cell osteoclastogenesis in vitro (Fig. 7d) without inducing apoptosis
2	(Fig. 7e), or altering TNF- α expression (Fig. 7f). FoxM1 deletion mitigated bone
3	erosion in vivo, which was partly reversed by the adoptive transfer of
4	FoxM1 ^{+/+} CX ₃ CR1 ⁺ monocytes but not by FoxM1 ^{-/-} CX ₃ CR1 ⁺ monocytes (Fig. 7g
5	and Supplementary Fig. <mark>13</mark> a, b). The arthritic score was also reduced by <mark>the</mark>
6	global FoxM1 deletion (Fig. 7h). By contrast, osteoclastogenesis by BM-OPs
7	was not affected by the FoxM1 deletion <i>in vitro</i> (Fig. 7d). Myeloid cell-specific
8	FoxM1 knockout mice (LysM-Cre:FoxM1 ^{fl/fl}) and global deletion beginning at 6
9	weeks of age resulted in no change in body growth or physiological bone
9 10	weeks of age resulted in no change in body growth or physiological bone remodelling (Supplementary Figs. 14 and 15).
9 10 11	weeks of age resulted in no change in body growth or physiological bone remodelling (Supplementary Figs. 14 and 15). To clarify the role of FoxM1 in the conversion of R2 into R3 cells, we sorted
9 10 11 12	weeks of age resulted in no change in body growth or physiological bone remodelling (Supplementary Figs. 14 and 15). To clarify the role of FoxM1 in the conversion of R2 into R3 cells, we sorted R2 cells from CAIA mice treated with or without tamoxifen (Supplementary Fig.
9 10 11 12 13	 weeks of age resulted in no change in body growth or physiological bone remodelling (Supplementary Figs. 14 and 15). To clarify the role of FoxM1 in the conversion of R2 into R3 cells, we sorted R2 cells from CAIA mice treated with or without tamoxifen (Supplementary Fig. 16a). Incubation with M-CSF successfully converted R2 cells into R3 cells in
9 10 11 12 13 14	 weeks of age resulted in no change in body growth or physiological bone remodelling (Supplementary Figs. 14 and 15). To clarify the role of FoxM1 in the conversion of R2 into R3 cells, we sorted R2 cells from CAIA mice treated with or without tamoxifen (Supplementary Fig. 16a). Incubation with M-CSF successfully converted R2 cells into R3 cells in both groups (FoxM1^{+/+} and FoxM1^{-/-}), indicating that FoxM1 is dispensable for
9 10 11 12 13 14 15	 weeks of age resulted in no change in body growth or physiological bone remodelling (Supplementary Figs. 14 and 15). To clarify the role of FoxM1 in the conversion of R2 into R3 cells, we sorted R2 cells from CAIA mice treated with or without tamoxifen (Supplementary Fig. 16a). Incubation with M-CSF successfully converted R2 cells into R3 cells in both groups (FoxM1^{+/+} and FoxM1^{-/-}), indicating that FoxM1 is dispensable for upregulation of CX₃CR1 and downregulation of Ly6C (Supplementary Fig. 16b).

RA synovial CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁺ cells have high osteoclastogenic potential

3	Finally, we examined the relevance of the osteoclastogenesis mechanism in
4	humans. Because Ly6C is not expressed in human cells, we used CX $_3$ CR1 and
5	HLA-DR (I-A/I-E in mice) to identify the subset with high osteoclastogenic
6	potential. We detected CX ₃ CR1 ⁺ HLA-DR ^{hi} CD14 ⁺ CD64 ⁺ cells ³⁶ in the synovial
7	fluid and synovium, but not in blood, of RA patients (Fig. 8a). Given that these
8	cells from synovial fluid and synovium of RA patients were negative for CD80,
9	positive for CD11c, and partially positive for CD86 (Fig. 8b), we further divided
10	CX₃CR1⁺HLA-DR ^{hi} cells into CX₃CR1⁺HLA-DR ^{hi} CD11c⁺CD86⁻ cells (P1) and
11	CX₃CR1⁺HLA-DR ^{hi} CD11c⁺CD86⁺ cells (P2) (Fig. 8c). <mark>P2 cells had higher</mark>
12	potential for osteoclast formation and FoxM1 expression compared with P1 cells
13	(Fig. 8d, e) and thiostrepton significantly inhibited osteoclastogenesis by these
14	cells (Fig. 8f). Because P1 and P2 cells express CD86 over a continuous range
15	of values, without a clear threshold separating distinct subpopulations, some of

1 the P1 cells with relatively high FoxM1 expression also formed osteoclasts (Fig.

2 8g), and this was inhibited by thiostrepton (Fig. 8f).

3

4 Discussion

In this report, we provided a detailed assessment of the differentiation trajectory 5 of inflammatory OPs (Supplementary Fig. 17), and identified a distinct 6 arthritis-associated macrophage population, AtoM, which is responsible for 7 articular bone erosion in pannus. Although extensive studies have identified 8 monocytoid cells with osteoclastogenic potential in the BM or spleen under 9 various conditions^{8,9,10,13,37}, pathogenic osteoclasts formed on the pannus-bone 10 interface are derived from circulating blood monocytes which ingress into the 11 synovium, and a precise analysis of the inflamed synovium is indispensable to 12 identify the in situ OP population in the arthritic condition. Our protocol 13 succeeded in isolating the inflamed synovium on the bare area¹¹, which can be 14 confirmed by its unique flow cytometric plots compared with those of other 15 (Supplementary Fig. 4b). We also demonstrated that 16 organs

1	CD45 ⁺ CX ₃ CR1 ^{Io} Ly6C ^{hi} populations in the blood (R1) and inflamed synovium
2	(R2) have substantially distinct transcriptional profiles in terms of chemokines
3	(Cxcl1, Cxcl2, Ccl2, Ccl3, and Ccl4) and inflammatory cytokines (II1, II6, and
4	Tnf). Distinguishing synovial cells from BM cells enabled us to identify a unique
5	macrophage population, AtoM, suggesting that macrophage subtypes in vivo
6	should be defined depending on the residing organs and corresponding
7	diseases, rather than the simple terminology of M1 and M2 macrophages.
8	Notably, AtoMs highly express several cell surface molecules for antigen
9	presentation, including MHC class II and CD80/86 (Fig. 2g). Despite its
10	controversy, this result may suggest that osteoclasts in arthritic joints derived
11	from AtoMs are involved in antigen presentation in local foci. A previous study of
12	inflammatory bowel disease reported that osteoclasts generated under
13	inflammatory conditions are efficient at inducing TNF- α -producing CD4 ⁺ T cells,
14	amplifying both the inflammatory response and bone destruction ¹⁰ . Other studies
15	have also demonstrated that dendritic cells (DCs) can differentiate into
16	osteoclasts under inflammatory conditions ^{38,39} . Although the F4/80 expression

and structural phenotype of AtoMs (e.g., vacuolar cytoplasm) suggest that they
can be classified as macrophages, the expression of DC markers such as
CD11c and MHC class II imply that AtoMs may share functional characteristics
with both macrophages and DCs.

FoxM1 plays a prominent role in carcinogenesis by rendering tumour cells 5 more aggressive and invasive²⁴; however, it has never been reported in the 6 context of autoimmune diseases. A previous study showed that FoxM1 directly 7 drives mitochondrial biogenesis⁴⁰, which is crucial for differentiation into 8 osteoclasts⁴¹, and our RNA-Seq data are consistent with this finding, in that 9 AtoMs were significantly enriched with genes associated with mitochondrial 10 translation and oxidative phosphorylation (Supplementary Fig. 7c). Thus, FoxM1 11 may play a role in AtoMs by meeting the high energy demand for 12 osteoclastogenesis under arthritic conditions. Because global FoxM1 inhibition 13 alleviated not only articular bone destruction but also inflammation, it is possible 14 that other cells outside of the myeloid lineage influence the inflammatory 15 process via FoxM1, which can indirectly affect bone destruction. Future studies 16

1 are needed to advance our knowledge on this subject.

2	In human cells, several studies have reported that macrophages in the
3	synovial fluid and synovium of RA patients express CX ₃ CR1 ^{42–44} ; HLA-DR has
4	also been used to categorize human blood monocytes ¹⁶ . Because mouse AtoMs
5	express CX ₃ CR1 and I-A/I-E, the application of these two markers in samples
6	from RA patients facilitated identification of the CX ₃ CR1 ⁺ HLA-DR ^{hi} population
7	only in the synovial samples and we further revealed that human synovial OPs
8	were included in the CX ₃ CR1 ⁺ HLA-DR ^{hi} CD11c ⁺ CD86 ⁺ population. An
9	anti-fractalkine monoclonal antibody phase-1/2 clinical trial demonstrated an
10	effective clinical response in active RA patients ⁴⁵ , and further analysis of
11	osteoclastogenesis and chemotactic activity in these cells may improve our
12	understanding of its pathophysiology in RA.
13	Our protocol allows for the precise isolation of inflamed synovium from

arthritic mice and may facilitate investigations to determine the role of other immune cells involved in pannus *in situ*, including lymphocytes, fibroblasts, and endothelial cells. In addition, although cytokine-inhibiting biological agents in

1	current clinical use have drawbacks related to increased susceptibility to
2	infection, the direct targeting of FoxM1 may facilitate the development of
3	pathogenic osteoclast-targeted treatment. This is distinct from therapies
4	targeting CX ₃ CL1 (fractalkine) because CX ₃ CR1 ⁺ cells do not necessarily
5	depend on the CX ₃ CL1-CX ₃ CR1 axis for chemotaxis within the synovial tissue
6	and chemotaxis is not directly involved in osteoclastogenesis. Furthermore,
7	pathological bone destruction represents a final common pathway in <mark>several</mark>
8	chronic inflammatory disorders, including histiocytosis, spondyloarthritis, and
9	sarcoidosis, which are responsible for substantial disability and morbidity ⁶ . The
10	identification of arthritis-associated OPs <mark>implies</mark> that the resultant osteoclasts
11	<mark>are</mark> more heterogeneous than presently <mark>thought</mark> , and <mark>an</mark> understanding <mark>of</mark> the
12	dynamics of pathological osteoclastogenesis should prompt the development of
13	optimized treatment for inflammatory bone destruction.
14	
15	1. Pirzgalska, R. M. <i>et al.</i> Sympathetic neuron-associated macrophages

16 contribute to obesity by importing and metabolizing norepinephrine. *Nat.*

1		<i>Med.</i> 23 , 1309–1318 (2017).
2	2.	Okabe, Y. & Medzhitov, R. Tissue-specific signals control reversible
3		program of localization and functional polarization of macrophages. <i>Cell</i>
4		157 , 832–844 (2014).
5	3.	Satoh, T. et al. Identification of an atypical monocyte and committed
6		progenitor involved in fibrosis. <i>Nature</i> 541 , 96–101 (2017).
7	4.	Asano, K. et al. CD169-positive macrophages dominate antitumor
8		immunity by crosspresenting dead cell-associated antigens. Immunity 34,
9		85–95 (2011).
10	5.	Arai, F. et al. Commitment and differentiation of osteoclast precursor cells
11		by the sequential expression of c-fms and receptor activator of nuclear
12		factor кb (Rank) receptors. <i>J. Exp. Med.</i> 190 , 1741–1754 (2002).
13	6.	Schett, G. & Gravallese, E. Bone erosion in rheumatoid arthritis:
14		Mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol. 8, 656–664
15		(2012).
16	7.	McInnes, I. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365,

1 **2205–19 (2011)**.

2	8.	Charles, J. F. et al. Inflammatory arthritis increases mouse osteoclast
3		precursors with myeloid suppressor function. J. Clin. Invest. 122, 4592–
4		4605 (2012).
5	9.	Seeling, M. et al. Inflammatory monocytes and Fc receptor IV on
6		osteoclasts are critical for bone destruction during inflammatory arthritis in
7		mice. <i>Proc. Natl. Acad. Sci.</i> 110 , 10729–10734 (2013).
8	10.	Ibáñez, L. <i>et al.</i> Inflammatory osteoclasts prime TNFα-producing CD4+ T
9		cells and express CX3CR1. <i>J. Bone Miner. Res.</i> 31 , 1899–1908 (2016).
10	11.	Werner, D. et al. Early changes of the cortical micro-channel system in the
11		bare area of the joints of patients with rheumatoid arthritis. Arthritis
12		<i>Rheumatol.</i> 69 , 1580–1587 (2017).
13	12.	Adamopoulos, I. E. & Mellins, E. D. Alternative pathways of
14		osteoclastogenesis in inflammatory arthritis. Nat. Rev. Rheumatol. 11,
15		189–194 (2015).
16	13.	Jacome-Galarza, C. E., Lee, S. K., Lorenzo, J. A. & Aguila, H. L.

1		Identification, characterization, and isolation of a common progenitor for
2		osteoclasts, macrophages, and dendritic cells from murine bone marrow
3		and periphery. <i>J. Bone Miner. Res.</i> 28 , 1203–1213 (2013).
4	14.	Ishii, M. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors
5		and regulates bone homeostasis. <i>Nature</i> 458 , 524–528 (2009).
6	15.	Misharin, A. V <i>et al.</i> Non-classical Ly6C- monocytes drive the
7		development of inflammatory arthritis in mice. Cell Rep. 9, 591–604 (2014).
8	16.	Geissmann, F., Jung, S. & Littman, D. R. Blood monocytes consist of two
9		principal subsets with distinct migratory properties. <i>Immunity</i> 19 , 71–82
10		(2003).
11	17.	Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes
12		and tissue macrophages under homeostasis. <i>Immunity</i> 38 , 79–91 (2013).
13	18.	Yokota, K. <i>et al.</i> Combination of tumor necrosis factor α and interleukin-6
14		induces mouse osteoclast-like cells with bone resorption activity both in
15		vitro and in vivo. Arthritis Rheumatol. 66 , 121–129 (2014).
16	19.	O'Brien, W. et al. RANK-independent osteoclast formation and bone

1		erosion in inflammatory arthritis. Arthritis Rheumatol. 68, 2889–2900
2		(2016).
3	20.	Lam, J. <i>et al.</i> TNF- α induces osteoclastogenesis by direct stimulation of
4		macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest.
5		106 , 1481–1488 (2000).
6	21.	Ochi, S. et al. Pathological role of osteoclast costimulation in
7		arthritis-induced bone loss. Proc. Natl. Acad. Sci. 104, 11394–11399
8		(2007).
9	22.	Tamura, T. et al. Soluble interleukin-6 receptor triggers osteoclast
10		formation by interleukin 6. <i>Proc. Natl. Acad. Sci.</i> 90 , 11924–11928 (2006).
11	23.	Murata, K. et al. Hypoxia-sensitive COMMD1 integrates signaling and
12		cellular metabolism in human macrophages and suppresses
13		osteoclastogenesis. Immunity 47 , 66–79 (2017).
14	24.	Lam, E. WF., Brosens, J. J., Gomes, A. R. & Koo, CY. Forkhead box
15		proteins: tuning forks for transcriptional harmony. Nat. Rev. Cancer 13,
16		482–495 (2013).

1	25.	Wang, Z., Banerjee, S., Kong, D., Li, Y. & Sarkar, F. H. Down-regulation of
2		Forkhead Box M1 transcription factor leads to the inhibition of invasion and
3		angiogenesis of pancreatic cancer cells. Cancer Res. 67, 8293–8300
4		(2007).
5	26.	Hegde, N. S., Sanders, D. A., Rodriguez, R. & Balasubramanian, S. The
6		transcription factor FOXM1 is a cellular target of the natural product
7		thiostrepton. <i>Nat. Chem.</i> 3 , 725–731 (2011).
8	27.	Halasi, M. & Gartel, A. L. A novel mode of FoxM1 regulation: Positive
9		auto-regulatory loop. <i>Cell Cycle</i> 8 , 1966–1967 (2009).
10	28.	Kwok, J. MM. et al. Thiostrepton selectively targets breast cancer cells
11		through inhibition of forkhead box M1 expression. <i>Mol. Cancer Ther.</i> 7 ,
12		2022–2032 (2008).
13	29.	Mbalaviele, G., Novack, D. V., Schett, G. & Teitelbaum, S. L. Inflammatory
14		osteolysis: A conspiracy against bone. J. Clin. Invest 127, 2030–2039
15		(2017).
16	30.	Campbell, I. K., Rich, M. J., Bischof, R. J. & Hamilton, J. A. The

	colony-stimulating factors and collagen-induced arthritis: exacerbation of
	disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J.
	<i>Leukoc. Biol.</i> 68 , 144–150 (2000).
31.	Ando, W. et al. Imatinib mesylate inhibits osteoclastogenesis and joint
	destruction in rats with collagen-induced arthritis (CIA). J. Bone Miner.
	<i>Metab.</i> 24 , 274–282 (2006).
32.	Hamilton, J. A. Colony-stimulating factors in inflammation and
	autoimmunity. <i>Nat. Rev. Immunol.</i> 8 , 533–544 (2008).
33.	Campbell, I. K., lanches, G. & Hamilton, J. A. Production of macrophage
	colony-stimulating factor (M-CSF) by human articular cartilage and
	chondrocytes. Modulation by interleukin-1 and tumor necrosis factor α .
	<i>Biochim Biophys Acta</i> 1182 , 57–63 (1993).
34.	Nakano, K. et al. Rheumatoid synovial endothelial cells produce
	macrophage colony-stimulating factor leading to osteoclastogenesis in
	rheumatoid arthritis. <i>Rheumatology</i> 46 , 597–603 (2007).
35.	Hutamekalin, P. et al. Collagen antibody-induced arthritis in mice:
	 31. 32. 33. 34. 35.

1		Development of a new arthritogenic 5-clone cocktail of monoclonal
2		anti-type II collagen antibodies. J. Immunol. Methods 343, 49–55 (2009).
3	36.	Xue, J. et al. Transcriptome-based network analysis reveals a spectrum
4		model of human macrophage activation. <i>Immunity</i> 40 , 274–288 (2014).
5	37.	Šućur, A. et al. Induction of osteoclast progenitors in inflammatory
6		conditions: Key to bone destruction in arthritis. Int. Orthop. 38, 1893–1903
7		(2014).
8	38.	Wakkach, A. et al. Bone marrow microenvironment controls the in vivo
9		differentiation of murine dendritic cells into osteoclasts. <i>Blood</i> 112 , 5074–
10		5083 (2008).
11	39.	Rivollier, A. et al. Immature dendritic cell transdifferentiation into
12		osteoclasts: A novel pathway sustained by the rheumatoid arthritis
13		microenvironment. <i>Blood</i> 104 , 4029–4037 (2004).
14	40.	De Luca, A. et al. Mitochondrial biogenesis is required for the
15		anchorage-independent survival and propagation of stem-like cancer cells.
16		<i>Oncotarget</i> 6 , 14777–95 (2015).
1	41.	Ishii, K. A. <i>et al.</i> Coordination of PGC-1β and iron uptake in mitochondrial
----	------	--
2		biogenesis and osteoclast activation. Nat. Med. 15, 259–266 (2009).
3	42.	Ruth, J. H. et al. Fractalkine, a novel chemokine in rheumatoid arthritis and
4		in rat adjuvant-induced arthritis. Arthritis Rheum. 44, 1568–1581 (2001).
5	43.	Blaschke, S. et al. Proinflammatory role of fractalkine (CX3CL1) in
6		rheumatoid arthritis. <i>J. Rheumatol.</i> 30 , 1918–1927 (2003).
7	44.	Nanki, T., Imai, T. & Kawai, S. Fractalkine/CX3CL1 in rheumatoid arthritis.
8		<i>Mod. Rheumatol.</i> 7595 , 1–6 (2016).
9	45.	Tanaka, Y. <i>et al.</i> Safety, pharmacokinetics, and efficacy of E6011, an
10		antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on
11		rheumatoid arthritis. <i>Mod. Rheumatol.</i> 28, 58–65 (2018).
12		
13	Ackı	nowledgements
14	We t	hank Dr. Ronald N. Germain (NIAID/NIH, USA) for critically reviewing this
15	man	uscript. This work was supported by CREST, Japan Science and

17 Society for the Promotion of Science (JSPS to M.I.); Grant-in-Aid for Young

16

Technology Agency; Grants-in-Aid for Scientific Research (S) from the Japan

1	Scientists (A) from JSPS (to J.K.); grants from the Uehara Memorial Foundation
2	(to M.I.); from the Kanae Foundation for the Promotion of Medical Sciences (to
3	M.I.); from Mochida Memorial Foundation (to M.I.); and from the Takeda Science
4	Foundation (to M.I.). The English in this document has been checked by at least
5	two professional editors, both native speakers of English. For a certificate, please
6	see: http://www.textcheck.com/certificate/576gzq
7	
8	Author contributions
9	T.H and M.I. conceived the study. T.H and J.K designed the experiments. T.S,
10	Y.M, S.S, T.M, K.Y, and T.T discussed the experiments and results. K.E and M.H
11	provided the samples from RA patients. Y.Y, A.H, and V.K provided the FoxM1 $^{\ensuremath{\text{fl/fl}}}$
12	mouse line and A.H provided the RosaERT2Cre mouse line. D.O performed the
13	RNA-seq analysis and single cell RNA-seq analysis. T.H wrote the initial draft.
14	J.K and M.I. revised the final draft.
15	
16	Competing interests

17 The authors declare no competing interests.



2 Figure 1. Bone marrow-derived CX₃CR1⁺ cells differentiate into osteoclasts

3 in pannus.

- 4 **a**, *In vitro* differentiation of CX₃CR1⁺ cells isolated from inflamed synovium of
- ⁵ knee joints into OC-like cells upon RANKL stimulation. Bars, 100 μm
- 6 **b**, *Ex vivo* incubation of inflamed synovium of knee joints from double transgenic
- 7 mice (CX₃CR1-EGFP/TRAP-tdTomato) upon RANKL stimulation. Enlargement
- 8 of the boxed areas are displayed. Bars, 50 μm.

c, Representative confocal images of arthritic knee joints from CX₃CR1-EGFP
 transgenic mice with TRAP staining. The arrowhead indicates merged
 osteoclasts. BM: bone marrow, M: meniscus, S: synovium. Bars, 200 and 30
 μm.

d, Schematic diagram showing the experimental design for bone marrow
chimeric mice, and e, parabiotic mice with CIA.
f, Flow cytometry plots and cumulative data of CX₃CR1-EGFP⁺ cells from

8 inflamed knee joints of CX₃CR1-EGFP transgenic mice (control) and bone

9 marrow chimeric mice (BMT).

g, Representative confocal images and frequencies of TRAP-tdTomato⁺
 osteoclasts among TRAP staining⁺ osteoclasts in the inflamed knee joints of
 indicated chimeras. Bars, 200 μm.

h, Flow cytometry plots and cumulative data of CX₃CR1-EGFP⁺ cells from
 inflamed knee joints of indicated parabionts.

i, Representative confocal images and frequencies of TRAP-tdTomato⁺
 osteoclasts among TRAP staining⁺ osteoclasts in the inflamed knee joints of
 indicated parabionts. Bars, 150 and 50 μm.

4 Unpaired two-tailed t test (f, g, i). Mean \pm S.E.M. for each group. Symbols

5 represent individual mice.





3 synovium have high osteoclast differentiation potential.

1

a-c, Representative plots and quantification of CX₃CR1-EGFP⁺ cells in the
blood, bone marrow, and knee joints of control and CIA mice 1 week after
arthritis onset.

7 **d**, Definitions of R1, R2, and R3 cells in the blood and synovium of CIA mice.

1	e, Detection of R2 and R3 cells in the CIA knee synovium of wild-type (WT)
2	parabionts paired with CX ₃ CR1-EGFP transgenic mice.
3	f. Adoptive transfer of CellTrace Violet-labelled R2 cells from the inflamed knee
4	synovium of CX ₃ CR1-EGFP transgenic mice into the inflamed knee joints of WT
5	mice.
6	g, FACS-based phenotypic characterization of R1, R2, and R3 cells with
7	indicated cell surface markers. Shaded regions indicate staining with isotype
8	controls. Dot plots of FSC-A/SSC-A are displayed with an overlay of R1 cells
9	from blood, and R2 and R3 cells from knee synovium.
10	h, Morphological assessment of R1, R2', and R3' cells with May–Giemsa
11	staining. Bar, 20 μm.
12	i, Osteoclast differentiation and resorption potential of R1, R2', R3' cells, and
13	OP-containing population from bone marrow (BM-OPs). R1, R2', R3' cells, and
14	BM-OPs were sorted and directly stimulated with 100 ng/ml RANKL and 10
15	ng/ml M-CSF for 6 days.

¹⁶ Unpaired two-tailed *t* test (a–c) and one-way ANOVA with Bonferroni's post hoc

test (i). Mean ± S.E.M. for each group. Symbols represent individual mice
except for the control group in c, where multiple mice were used for a single
symbol because of the limited number of cells in the uninflamed condition.



2 Figure 3. The RANKL-RANK-OPG axis is essential for R3' cell

3 osteoclastogenesis.

1

a. Representative TRAP staining images of synovial R3' cells from knee and ankle

- joints cultured with 10 ng/ml M-CSF, 50 ng/ml RANKL, 50 ng/ml TNF- α , or 50
- 6 ng/ml IL-6, either alone or in combination. Bars, 200 μm.
- 7 **b**, Quantification of nuclei within multinucleated cells within the visual field in **a**.

c, Representative TRAP staining images of R3' cells cultured with 10 ng/ml
 M-CSF, 50 ng/ml RANKL, and 50 ng/ml TNF-α with osteoprotegerin (OPG) at the
 indicated concentrations. Bars, 200 μm.
 d, Quantification of nuclei within multinucleated cells within the visual field in c.

- ⁵ One-way ANOVA test with Bonferroni post-hoc test (b, d). Mean ± s.e.m. for
- 6 each group. Symbols represent individual mice.







- 3 regulator of R3' cells.
- 4 **a**, Scatter plot analysis and principal component analysis (PCA) of R1, R2', and
- 5 R3' cells by RNA-Seq.

1	b, The top 300 upregulated genes from R1 to R2' cells, and c, R2' to R3' cells.
2	d, Expression analysis of osteoclast marker genes in R3' cells. Values indicate
3	the fold change of FPKM in R3'/R2' cells.
4	e, Enrichment analysis of osteoclast differentiation and fusion genes in R3' cells
5	compared to R2' cells.
6	f, Upstream regulator analysis of differentially expressed genes among
7	upregulated transcription factors in R3'.
8	g, RT-PCR analysis of FoxM1 expression in R2' cells, R3' cells, T lymphocytes,
9	and neutrophils from the inflamed synovium.
10	h, Representative histogram plots and quantitative MFI of FoxM1 expression in
11	R2' and R3' cells. Shaded regions indicate staining with isotype control.
12	i, RT-PCR analysis of FoxM1 expression in R3' cells after incubation with
13	thiostrepton for 48 hours.
14	j, Inhibition of RANKL-induced osteoclastogenesis of R3' cells by thiostrepton.

15 Bar, 100 μm.

k, Clinical arthritic scores of CIA mice treated with vehicle, 20 mg/kg, or 50
 mg/kg thiostrepton.

3 I, Representative 3D reconstructions and erosion scores of rear paws by

4 micro-CT analysis.

5 **m**, Histological examination of inflamed knee joints. Images are representative

 $_{6}$ of at least three similar experiments. Bars, 300 and 100 μ m.

7 Paired two-tailed *t* test (h) and one-way ANOVA with Bonferroni's post hoc test

8 (g, i, j, l). Mean ± S.E.M. for each group. Symbols represent individual mice.



1

2 Figure 5. Single cell RNA-sequencing analysis of synovial R3 cells

a, Schematic diagram outlining the single cell RNA-sequencing analysis. R3

- 4 cells were isolated from inflamed knee synovium 1 week after CIA onset.
- 5 **b**, t-SNE plot of the single cell RNA-seq data of 8,682 R3 cells from CIA mice.
- 6 Hierarchical clustering based on gene expression profiles was performed by BD
- 7 Data View software.

c, Differential expression analysis of cluster P1 and the other cell clusters. Fold
 change and significance level (*p*-value) were calculated for differentially
 expressed genes.

d, Single gene expression plot on t-SNE plot of the single cell RNA-seq data.





3 expression.

1	a, FoxM1 RT-PCR analysis in FACS-sorted R2 cells from inflamed knee joints
2	after incubation with the indicated cytokines for 72 hours. Nunclon Sphera plates
3	were used for non-adherent conditions. 10 ng/ml M-CSF, 100 ng/ml RANKL, 100
4	ng/ml TNF- α , and 100 ng/ml IL-6 were used. For the M-CSF (–) group, R2 cells
5	were sorted and directly examined by RT-PCR analysis.
6	b, Representative plots of FACS-sorted R2 cells from inflamed knee joints
7	before and after incubation with 10 ng/ml M-CSF. Similar results were obtained
8	in three independent experiments.
9	c, M-CSF western blot analysis of CIA knee synovium, control bone marrow, and
10	bone marrow from CIA mice.
11	d, Representative confocal images of control and CIA knee synovium stained
12	with anti-M-CSF biotinylated antibody, followed by staining with
13	streptavidin-FITC.
14	e, Gating strategy for leukocytes (Lin ⁺ CD45 ⁺ cells), endothelial cells
15	(Lin ⁻ CD45 ⁻ CD31 ⁺ CD140a ⁻ cells), and fibroblasts (Lin ⁻ CD45 ⁻ CD140a ⁺ CD31 ⁻
16	cells) in the inflamed knee synovium of CIA mice.

- 1 f, M-CSF, RANKL, IL-6, and TNF RT-PCR analysis in FACS-sorted leukocytes,
- 2 endothelial cells, and fibroblasts according to the protocol in **e**.
- ³ One-way ANOVA with Bonferroni's post hoc test (a, f). Mean ± S.E.M. for each
- 4 group. Symbols represent individual mice.



2 Figure 7. FoxM1 contributes to arthritis-induced bone destruction

3 a, Experimental design schematic for the collagen antibody-induced arthritis

- 4 (CAIA) model.
- 5 **b**, Semi-quantitative PCR analysis to detect the deletion of FoxM1 (*FoxM1*⁻) and
- 6 the loxP-flanked FoxM1 allele (*FoxM1^{fl}*) in the genomic DNA of bone marrow
- 7 cells.

1	c, FoxM1 RT-PCR analysis in CX ₃ CR1 ⁺ monocytes/macrophages, CD3 ⁺ T
2	lymphocytes, and Ly6G ⁺ neutrophils in bone marrow treated with oil control or
3	tamoxifen <i>in vivo</i> .
4	d, RANKL-induced osteoclastogenesis of R3 cells from inflamed knee synovium
5	and BM-OPs from control BM with vehicle or 4 μ M 4-hydroxytamoxifen (OHT).
6	Bars, 200 μm.
7	e, Flow cytometry analysis of annexin-V and propidium iodide (PI) positive
8	synovial R3 cells treated with vehicle or 4 μ M 4-OHT for 72 hours.
9	f, Enzyme-linked immunosorbent assay (ELISA) of TNF- α in cell culture
10	supernatant of synovial R3 cells treated with vehicle or 4 μ M 4-OHT for 48 hours.
11	g, Representative 3D reconstructions and erosion scores of rear paws by micro
12	CT analysis. CAIA mice treated with oil control, tamoxifen, tamoxifen plus
13	adoptive transfer of FoxM1 ^{+/+} CX ₃ CR1 ⁺ cells or FoxM1 ^{-/-} CX ₃ CR1 ⁺ cells were
14	analyzed.
15	h, Clinical arthritic scores of CAIA mice.

¹⁶ Unpaired two-tailed *t* test (c, d, e, f) and one-way ANOVA with Bonferroni's post

hoc test (g). Mean ± S.E.M. for each group. Symbols represent individual mice.





3 osteoclastogenic potential

- a, Phenotypic characterization of CD45⁺CX₃CR1⁺HLA-DR⁺ cells in the blood,
- 5 synovial fluid, and synovium of RA patients.
- 6 **b**, Phenotypic characterization with indicated cell surface markers on
- 7 CX₃CR1⁺HLA-DR^{hi} cells of synovial fluid and synovium of RA patients. Shaded
- 8 regions indicate staining with isotype controls.

- **c**, Contour plots of CD45⁺CX₃CR1⁺HLA-DR^{hi} cells gated by CD11c and CD86.
- 2 CD11c⁺CD86⁻ cells were termed P1 cells and CD11c⁺CD86⁺ cells were termed
- 3 **P2 cells**.
- 4 **d**, RANKL-induced osteoclastogenesis of CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁻ cells
- 5 (P1) and CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁺ cells (P2) from synovial fluid of RA
- 6 patients. Bars, 200 μm.
- 7 **e**, FoxM1 RT-PCR analysis in CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁻ cells (P1) and
- 8 CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁺ cells (P2).
- 9 **f**, RANKL-induced osteoclastogenesis of CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁻ cells
- 10 (P1) and CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁺ cells (P2) treated with DMSO or 0.1
- 11 μM thiostrepton. Bars, 200 μm.
- 12 g, Correlation of osteoclastogenic ability and relative FoxM1 expression in
- 13 CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁻ (P1) and CX₃CR1⁺HLA-DR^{hi}CD11c⁺CD86⁺
- 14 cells (P2). *r* = correlation coefficient.
- 15 One-way ANOVA with Bonferroni's post hoc test (a) and unpaired two-tailed t
- 16 test (d, f). Mean ± S.E.M. for each group. Symbols represent individual human

1 patients.

1 Methods

2 **Mice.**

WT DBA-1/J mice were obtained from Oriental Yeast Co. in Japan. 3 CX₃CR1-EGFP knock-in mice⁴⁶ and TRAP promoter-tdTomato transgenic 4 mice⁴⁷ derived from the C57BL/6 (B6) background were backcrossed >10 5 generations onto DBA-1/J mice. The FoxM1 LoxP/LoxP (fl/fl) mice were bred 6 with Rosa26-CreERT2 mice by one of our co-authors, Dr. Hirao (Kanazawa 7 University, Japan). LysM-Cre transgenic mice were provided by Dr. Shizuo 8 Akira (Osaka University, Japan)⁴⁸. All mice were bred and maintained under 9 specific-pathogen-free conditions at the animal facilities of Osaka University, 10 and all animal experiments were performed in accordance with the Osaka 11 University Animal Experimental Guidelines using approved protocols. Mutant 12 mice were genotyped by PCR. Following primers were used to detect FoxM1 13 flox allele and deleted FoxM1 allele; FoxM1 flox allele 14 (TGGCTTCCCAGCAGTACAAATC and TGCTTACAAAAGACACACTTGGACG), 15 deleted FoxM1 allele (TGGCTTCCCAGCAGTACAAATC 16 and

1 TCTCGCTCAATTCCAAGACCAG).

2

3 Samples from RA patients.

Research involving human subjects was approved by the Institutional Review 4 Board of Osaka University with appropriate informed consent. All RA subjects 5 with RA fulfilled the ACR 2010 Rheumatoid Arthritis classification criteria. 6 Clinical information, including seropositivity and medication usage, was obtained 7 8 by review of electronic medical records (Supplementary Table 2). Synovial tissue specimens were obtained from RA patients undergoing joint replacement 9 surgery or synovectomy at Osaka University Hospital. The tissue was minced 10 and digested with 3 mg/ml type I collagenase (Worthington) in HBSS, and 11 incubated at 37°C for 30 min, with inversion every 5 min. Disaggregated tissue 12 elements were passed through a 70 µm cell strainer. Synovial fluid samples 13 were obtained as excess material from RA patients with knee effusion 14 undergoing therapeutic arthrocentesis. Blood samples were obtained from RA 15

patients and subjected to density centrifugation using Lymphoprep (AXS) to
 isolate mononuclear cells.

3

4 Induction and evaluation of collagen-induced arthritis (CIA).

Arthritis was induced in DBA-1/J mice (Oriental Yeast Co.) between 8 and 10 5 weeks of age as described previously⁴⁹. Chicken type II collagen (cCII; Sigma 6 Chemical Co.) was dissolved in 0.05 M acetic acid to a concentration of 4 mg/ml 7 by overnight rotation at 4°C and mixed with an equal volume of Freund's 8 complete adjuvant (2 mg/ml of Mycobacterium tuberculosis; Chondrex). On day 9 0, DBA-1/J mice were immunized at the base of the tail with 100 µl of emulsion. 10 The same injection was repeated on day 21. The severity of arthritis was 11 evaluated using an established semi-quantitative scoring system with a 12 five-point scale, where 0 = no swelling, 1 = mild swelling confined to the tarsals 13 or ankle joint, 2 = mild swelling extending from the ankle to the tarsals, 3 = 14 moderate swelling extending from the ankle to metatarsal joints, and 4 = severe 15 swelling encompassing the ankle, foot, and digits. The cumulative score for the 16

four paws of each mouse (maximum score 16) was used as the arthritis score to
 represent overall disease severity, as described previously⁴⁹.

4	Induction and evaluation of collagen antibody-induced arthritis (CAIA).
5	Arthritis was induced by injecting 5 mg of 5-clone Arthrogen-CAIA antibody
6	(Chondrex) intravenously on day 0, and 40 μg of lipopolysaccharide
7	intraperitoneally on days 3 and 10. Mice were evaluated on day 14. The severity
8	of arthritis was evaluated with the same semi-quantitative method used for the
9	CIA model.
10	For FoxM1 ^{+/+} monocyte adoptive transfer, CX ₃ CR1 ⁺ Ly6C ^{hi} monocytes from
11	the BM of WT mice were sorted using an SH800 cell sorter (Sony). For FoxM1-/-
12	monocyte adoptive transfer, CX ₃ CR1 ⁺ Ly6C ^{hi} monocytes from the bone marrow
13	of FoxM1 ^{fl/fl} Rosa26 ^{CreERT2} mice treated with 2 mg tamoxifen for 5 days were
14	sorted. Aliquots of 1×10^6 cells per mouse were administered intravenously to
15	the tamoxifen-treated mice intravenously on days 1, 6, and 12.

1 Induction of DSS colitis.

To induce acute colitis, mice received 2% dextran sulphate sodium (DSS) salt (Wako) *ad libitum* in sterile drinking water. Mice were then sacrificed on day 6.

5 Parabiosis.

Male 8 week-old double transgenic mice (CX₃CR1-EGFP/TRAP-tdTomato) were 6 surgically connected to wild-type mice as described previously⁵⁰. The mice were 7 anesthetized with isoflurane. The lateral aspects of each mouse were shaved 8 and treated with hair-removal lotion (Epilat; Kracie Holdings). After 9 corresponding lateral skin incisions were made from elbow to knee in each 10 mouse, the forelimbs and hind limbs were tied together using silk sutures. 11 Incisions of approximately 1 cm were made in the peritoneum of each mouse, 12 and the mice were attached using silk sutures. The skin incisions were closed 13 using stainless steel wound clips. To ensure the animals' wellbeing for 8 weeks, 14 individual parabiotic mouse pairs were placed in clean cages, and food pellets 15 were broken into pieces, soaked in water, and placed on the floor to minimize 16

the strain of reaching for food. Shared blood circulation was confirmed by the 1 presence of EGFP⁺ monocytes in the peripheral blood of wild-type parabionts. 2 3 Bone marrow transplantation. 4 Recipient mice were administered a single 10-Gy dose of whole-body irradiation. 5 After 6 h, 3 million unfractionated bone marrow cells from donor mice were 6 injected intravenously. Bone marrow reconstitution was confirmed by 7 immunohistological analysis of tdTomato and EGFP⁺ cells in the bone marrow at 8 the observation endpoint. 9 10 Isolation of leukocytes from tissues. 11 12 Tissues were harvested and prepared as follows. After sacrifice under

anaesthesia, the right auricles of the mice were cut and 15 ml of pre-warmed 1×

PBS was injected into the left ventricle for perfusion. Perfusion was omitted in

15 experiments designed to assess blood samples.

Because knee joints are covered with muscles, direct macroscopic 1 observation of arthritis is challenging. Therefore, we selected mice with arthritic 2 paws and confirmed substantial inflammation in knee joints by direct exposure of 3 the inflamed synovium using the following protocol. Mice were perfused with 15 4 ml of pre-warmed 1× PBS. After the removal of the skin and biceps femoris 5 muscle, the quadriceps femoris muscles including the vastus intermedius 6 muscle were pinched and lifted with tweezers. The guadriceps femoris muscles 7 and patellar ligament, including the patella, were removed from the knee joint 8 under a stereoscopic microscope (SMZ 745T, Nikon). The hypertrophied 9 synovium was isolated without damaging the bone (Supplementary Fig. 1b). 10 Ankle joint tendons, including the Achilles tendon, were removed revealing the 11 hypertrophied synovium around the talus, which allowed for isolation without 12 damaging the bone (Supplementary Fig. 1d). Synovial tissues were digested 13 with 3 mg/ml type I collagenase in HBSS, and incubated at 37°C for 30 min. 14 Disaggregated tissue elements were passed through a 70 µm cell strainer. 15

1	The bone marrow, spleen, and liver were minced and passed through a 70
2	μm cell strainer. The kidney, lung, and brain were harvested, minced, and
3	digested for 30 min in RPMI containing 1 mg/ml type I collagenase (Worthington)
4	and 5% heat-inactivated foetal bovine serum (FBS) at 37°C to obtain single-cell
5	suspensions. For isolation of colonic lamina propria cells, the entire colon was
6	cut longitudinally and washed to remove all excess fat and faeces. The tissues
7	were then incubated in calcium/magnesium-free Hank's Balanced Salt Solution
8	(HBSS) containing 5 mM EDTA at 37°C for 20 min on a shaking incubator. After
9	removal of epithelial cells, the tissues were finely minced and incubated in RPMI
10	containing 1 mg/ml type IV collagenase, 600 U/ml DNase IV (Qiagen), 0.5 mg/ml
11	of Dispase (Invitrogen), and 5% FBS for 50 min at 37°C in a shaking incubator.
12	The resulting cell suspension was passed through a 70 μm cell strainer, and
13	centrifuged at 1500 rpm for 5 min to prepare for FACS analysis.

15 Flow cytometry.

1	Measurements were performed on an SH800 cell sorter (Sony) and analyzed
2	with FlowJo software (TreeStar). Isolated murine cells were blocked with
3	anti-CD16/32 antibody (553141; BD Biosciences) for 10 min, followed by
4	staining with the following antibodies for 15 min: anti-CD45-PB (103126;
5	BioLegend), anti-CD80-PB (104724; BioLegend), anti-CD86-PB (105021;
6	BioLegend), anti-CD3-BV421 (100227; BioLegend), anti-Ly6G-BV421 (127627;
7	BioLegend), Streptavidin-BV421 (405226; BioLegend), anti-F4/80-BV421
8	(123137; BioLegend), anti-CD11b-BV421 (101235; BioLegend),
9	anti-I-A/I-E-Biotin (107603; BioLegend), anti-CD11c-Biotin (117303; BioLegend),
10	anti-CD265 (RANK)-Biotin (13-6612-81; eBioscience), Lineage cell detection
11	cocktail-Biotin (130-092-613; Miltenyi Biotec), anti-CD3-PE (100308; BioLegend)
12	anti-CD140a-PE (135905; BioLegend), anti-CD45-FITC (103108; BioLegend),
13	anti-CX ₃ CR1-FITC (149019; BioLegend), anti-Ly6C-APC (560595; BD
14	Biosciences), anti-CX ₃ CR1-APC (149007; BioLegend), Annexin V-APC
15	(640919; BioLegend), anti-CD45-PE/Cy7 (103114; BioLegend),
16	anti-CD31-AF647 (102516; BioLegend), anti-CD11b-PE/Cy7 (552850; BD

1	Biosciences), anti-F4/80-PE/Cy7 (123113; BioLegend), anti-CCR2-PE/Cy7
2	(150611; BioLegend), Biotin-Rat IgG2a,κ isotype control (400503; BioLegend),
3	PB-Rat IgG2a,κ isotype control (400527; BioLegend), PB-Armenian Hamster
4	IgG isotype control (400925; BioLegend), BV421-Rat IgG2a, κ isotype control
5	(BD Biosciences), and PE/Cy7-Rat IgG2a, κ isotype control (400521;
6	BioLegend). Annexin V-BV421 (640923; BioLegend) and Propidium iodide (PI)
7	solution (421301; BioLegend) were used to evaluate apoptosis.
8	The following antibodies were used for human samples:
9	anti-HLA-DR-BV421 (307635; BioLegend), anti-CD64-FITC (305005;
10	BioLegend), anti-CD86-FITC (374203; BioLegend), anti-CD14-PE (325605;
11	BioLegend), anti-CX ₃ CR1-APC (341609; BioLegend), anti-CD80-PerCP/Cy5.5
12	(305231; BioLegend), anti-CD45-PE/Cy7 (304015; BioLegend),
13	anti-CD11c-PE/Cy7 (561356; BD Biosciences), PE-mouse IgG1κ isotype control
14	(400111; BioLegend), FITC-mouse IgG1κ isotype control (400107; BioLegend),
15	PerCP/Cy5.5-mouse IgG1κ isotype control (400149; BioLegend), and Fc blocker
16	(422301; BioLegend).

1	For intracellular FoxM1 staining, 200 µl of fixation/permeabilization working
2	solution (00-5523-00; eBioscience) was added to each sample, and incubated
3	for 60 min at room temperature. After blockade with anti-CD16/32 antibody,
4	FoxM1 antibody (175798; Abcam) in 100 µl of permeabilization buffer
5	(00-5523-00; eBioscience) was added to each sample. Samples were
6	subsequently incubated for 60 min at room temperature, and then washed with
7	200 µl of permeabilization buffer. Anti-rabbit biotinylated antibody (BA-1000;
8	Vector) was added in 50 μl of permeabilization buffer and samples were
9	incubated for 30 minutes at room temperature, washed with 200 μ l of
10	permeabilization buffer, and then stained with Streptavidin-PE (405203;
11	BioLegend) or Streptavidin-BV421 (405226; BioLegend) for 30 min at room
12	temperature. Normal rabbit IgG (sc-2027; Santa Cruz Biotechnology) was used
13	as a control antibody.

15 Histology and immunohistochemistry.

1	Mice were euthanized at various time points and tissues were fixed by perfusion
2	with 4% paraformaldehyde (PFA). Dissected knee joints were further fixed with
3	4% PFA for 3 h at 4°C. The samples were frozen in chilled hexane (Wako) using
4	dry ice, and 12-µm-thick sections of non-decalcified knee joints were prepared
5	using a Multi-Purpose Cryosection Preparation Kit ⁵¹ (Section-Lab and Leica
6	Microsystems). A standard protocol was used for haematoxylin and eosin (H&E)
7	staining, and immunohistological analyses were performed as described
8	previously ¹⁴ . Fluorescence-based staining for tartrate-resistant acid phosphate
9	(TRAP) with ELF97 substrate (Life Technologies) was used with some
10	modifications. Anti-M-CSF antibody (sc-365779; Santa Cruz Biotechnology) was
11	biotinylated in our laboratory using a Biotin Labelling Kit-NH ₂ (Dojindo Molecular
12	Technologies Inc.). Samples were stained with anti-M-CSF biotinylated antibody
13	in TBS-T for 60 min at room temperature, followed by staining with
14	Streptavidin-FITC (405201; BioLegend) for 60 minutes at room temperature.
15	Samples were observed using a TCS-SP5 confocal microscope (Leica
16	Microsystems) and illuminated with a laser (wavelength: 405 nm for ELF97 and
1	BV421, 488 nm for EGFP, and 561 nm for PI and tdTomato). Collagen-enriched
----	--
2	bone matrices and synovial fibrous tissues were visualized using the second
3	harmonic generation (SHG) with infrared lasers of a TCS-SP5 multi-photon laser
4	microscope (wavelength 880 nm) driven by a Chameleon XR Sapphire laser
5	(Coherent), which also excite EGFP. Emission signals were obtained by setting
6	the wavelength to 420–470 nm for BV421, 500–550 nm for ELF97, EGFP, and
7	FITC, 580–630 nm for tdTomato, 600–630 nm for PI, and 430–480 nm for SHG.
8	For cell counting of healthy synovium, synovial fibres and bones were identified
9	with SHG, and three knee joint sections per mouse were analyzed using Imaris
10	software (Bitplane) (Supplementary Fig. 2a). Knee joints were used for
11	histological examination because articular anatomical structures, such as
12	synovium and bare area, were easily discerned microscopically in both inflamed
13	and uninflamed conditions, unlike paws, where small tarsal bones tightly adhere
14	to each other.

16 Real-Time PCR Analyses.

1	Total RNA	and cDNA	of the cells f	rom each tiss	ue were obta	ined with an
2	RNeasy Mir	ni Kit (Qiag	jen) and Supe	erscript III reve	erse transcript	ase (Thermo
3	Fisher Scier	ntific), acco	ording to the	manufacturers	instructions.	Quantitative
4	real-time (R	T) PCR wa	s performed fo	or 40 cycles us	sing a Therma	l Cycler Dice
5	Real-Time S	System TP8	800 (Takara). ⁻	The reactions	were normaliz	ed relative to
6	the houseke	eping gene	β -Actin, and the set of the se	ne specificity of	the amplified	products was
7	confirmed by	y dissociatio	on curves. The	e following spe	cific primer pai	rs were used
8	(forward	and	reverse,	respectively)	: mouse	β-actin
9	(5'-TCCTCC	CTGGAGA	AGAGCTA-3'	and 5'-ATCTC	CTTCTGCAT	CCTGTC-3');
10	mouse	FoxM1	(5'-GTCT	CCTTCTGGA	CCATTCACC-	3' and
11	5'-GCTCAG	GATTGGG	TCGTTTCTG-	3');	mouse	M-csf
12	(5'-CCCATA	TTGCGAC	ACCGAA-3'			and
13	5'-AAGCAG	TAACTGA	GCAACGGG-3	5');	mouse	Rankl
14	(5'-CAGCAT	СССТСТС	GTTCCTGTA-3	3		and
15	5'-CTGCGT	TTTCATGO	GAGTCTCA-3');	mouse	Tnf
16	(5'-GCCACC	CACGCTCI	TCTGTCTAC	-3'		and

1	5'-GGGTCTGGGCCATAGAACTGAT-3');	mouse	II-6
2	(5'-CACATGTTCTCTGGGAAATCG-3'		and
3	5'-TTGTATCTCTGGAAGTTTCAGATTGTT-3'),	mouse	II−1β
4	(5'-CTGCAGCTGGAGAGTGTGGAT-3'		and
5	5'-CTCCACTTTGCTCTTGACTTCTATCTT-3').		

7 RNA-Seq.

8 R1, R2', and R3' cells from three mice were isolated using an SH800 cell sorter (Sony) and total RNA was extracted using QIAzol lysis reagent (Qiagen), 9 according to the manufacturer's instructions. Sequencing was performed on an 10 Illumina HiSeq 2500 platform in 75-base single-end mode with Illumina Casava 11 12 1.8.2 software used for base-calling. Sequenced reads were mapped to the mouse reference genome sequences (mm10) using TopHat v2.0.13 in 13 combination with Bowtie2 ver. 2.2.3 and SAMtools ver. 0.1.19. Fragments per 14 kilobase of exon per million mapped fragments (FPKM) were calculated using 15 Cuffkinks version 2.2.1. The Subio Platform and Subio Basic Plug-in (v1.20; 16

1	Subio Inc., Aichi, Japan) were used to calculate the between-sample fold
2	change analyzed by two-tailed Student's t-test (p <0.1). Bioinformatics analyses
3	were performed with Ingenuity Pathway Analysis software (Ingenuity Systems;
4	Qiagen). The FPKM score was calculated based on the number of transcribed
5	fragments, and functional associations were computed using the Gene Set
6	Enrichment Analysis (GSEA) software (Broad Institute;
7	http://software.broadinstitute.org/gsea/index.jsp). Gene sets from the Broad
8	Institute Molecular Signatures Database and a modified gene set
9	(Supplementary Table 1) were used.
10	Upstream Regulator Analysis in QIAGEN's Ingenuity Pathway Analysis
11	(IPA; Qiagen) was performed to predict the activation or inhibition of transcription
12	factors based on the observed gene expression changes in the gene datasets
13	and the direction of expression changes in R2' vs. R3' cells. Statistical analysis
14	of the predictions was calculated by the activation z score, "which is designed
15	such that gene sets composed of randomly chosen perturbed genes with
16	random sign of fold change do not lead to significant results on average"

(Ingenuity Downstream Effects Analysis, whitepaper). The strongest predicted
 activation corresponds to z-scores ≥ 2, and the strongest predicted inhibition
 corresponds to z-scores ≤ -2.

4

5 Single cell RNA-sequencing analysis

R3 cells were isolated from the inflamed knee synovium of CIA mice 1 week after 6 arthritis onset. Then, targeted single-cell RNA-sequence analysis was 7 8 conducted using the BD Rhapsody Single-Cell Analysis System (BD BioScience), following the manufacture's protocol. In short, the single cell 9 suspension was loaded into a BD Rhapsody cartridge with >200,000 microwells 10 and single cell capture was achieved by random distribution and gravity 11 precipitation. Next, the bead library was loaded into the microwell cartridge to 12 saturation, to promote the pairing of each cell with a bead. The cells were lysed 13 in the microwell cartridge to hybridize mRNA molecules to barcoded capture 14 oligos on the beads. Then, beads were collected from the microwell cartridge 15 into a single tube for subsequent cDNA synthesis, Exol digestion and 16

multiplex-PCR based library construction. For the library construction, we used 1 the customized BD Rhapsody Immune Response Panel for mouse (BD 2 BioScience) consisting of primer sets for 404 genes. Sequencing was performed 3 on an Illumina HiSeq 3000 platform. The BD Rhapsody Analysis Pipeline was 4 used to process the sequencing data (fastg files) and output result files were 5 analyzed and visualized by the BD Data view software (BD BioScience). Raw 6 reads from these samples were submitted to the National Center for 7 8 Biotechnology Information (NCBI) Gene Expression Omnibus database (accession no. GSM3712154). 9

10

11 Micro-computed tomography (micro-CT) of bone tissues.

With regard to bone erosion, arthritic hind limbs were scanned with micro-CT (ScanXmate-RX; Comscantechno Inc.), and 3D microstructure images were generated using TRI/3D-BON software (RATOC Systems). The severity of periarticular erosions was determined by two blinded observers (TH and JK) using a semi-guantitative method with modifications from a previous report¹⁹. Six

1	sites in the ankle joint were scored: the talus; the navicular bone; the medial
2	cuneiform bone; and the bases of the first, second, and third metatarsals
3	(Supplementary Fig. 9a). Each site was scored on a scale of 0–3 (0 = normal, 1
4	= pitting, 2 = full-thickness holes in small–medium areas, 3= full-thickness holes
5	in medium–large areas) with a maximum score of 18 as described in
6	Supplementary Fig 9b. The scores of the arthritic hind paw determined by the
7	two observers were averaged to obtain the final erosion score. Inter-observer
8	and intra-observer reproducibility are shown in Supplementary Fig. 9c, d. We
9	used ankles for micro CT analysis because official radiographic quantification of
10	bone erosion in human RA patients is done in wrists or ankles (Sharp score).
11	Trabecular bone morphometry within the metaphyseal region of the distal
12	femur was quantified using micro-CT. 3D microstructure images were generated
13	and bone analysis was performed using TRI/3D-BON software (RATOC
14	Systems), as described previously. ⁵²

16 Western blotting analysis.

1	Whole-cell protein extracts of inflamed synovium and bone marrow were
2	prepared using radioimmunoprecipitation assay (RIPA) buffer (1× PBS, 0.1%
3	sodium dodecyl sulphate (SDS), 1% NP40, 0.5% sodium deoxycholate)
4	supplemented with protease inhibitors (Sigma), and centrifuged at 4° C for 10
5	min at 14000 × g. Protein concentration was determined by BCA protein assay
6	(Thermo Scientific). Equal amounts of protein were subjected to electrophoresis
7	on 4%–15% gradient SDS-polyacrylamide gels (Bio-Rad) and transferred to
8	PVDF membranes. After blocking with PVDF blocking reagent (Toyobo), the
9	membranes were incubated with primary antibodies in Immunoreaction
10	Enhancer Solution 1 (Toyobo) for 1 h at room temperature followed by
11	incubation with secondary antibody in Immunoreaction Enhancer Solution 2
12	(Toyobo) for 1 h at room temperature. The following antibodies were used at the
13	indicated dilutions: β-actin (20272; Abcam; 1:1000), M-CSF (1:1000).

15 Analysis of TNF-α in cell culture supernatants

1	CAIA was induced in FoxM1 ^{fl/fl} Rosa26 ^{CreERT2} mice and 1 × 10 ⁴ R3 cells from
2	inflamed synovium of knee and ankle joints were sorted using SH800 (Sony).
3	After 48 h of incubation with EtOH or 4 μ M 4-hydroxytamoxifen (4-OHT), culture
4	medium was replaced and incubated for 24 h with 10 ng/ml M-CSF in minimal
5	essential medium (MEM). The TNF- α concentration in cell culture supernatant
6	was determined with the enzyme linked immunosorbent assay (ELISA), using
7	the Mouse TNF alpha ELISA Kit (ab100747; Abcam), based on the
8	manufacturer's protocol.
9	

10 Treatment with thiostrepton *in vivo*.

11 CIA mice were divided into three treatment groups: vehicle (20% 12 *N*,*N*-dimethylacetamide, 75% polyethylene glycol 400, and 5% Tween 80), 13 low-dose thiostrepton, and high-dose thiostrepton. Thiostrepton was injected 14 intraperitoneally at a dose of 20 mg/kg (low-dose) or 50 mg/kg (high-dose) every 15 other day for 3 weeks before sacrifice. For RT-PCR analyses of the inflamed synovium, CIA mice were sacrificed 2 weeks after starting treatment with vehicle
or 50 mg/kg thiostrepton injection every other day.
For the physiological bone remodelling analyses, male mice were divided
into two groups: vehicle (20% *N*,*N*-dimethylacetamide, 75% polyethylene
glycol 400, and 5% Tween 80), and 50 mg/kg thiostrepton. Vehicle or
thiostrepton was injected intraperitoneally twice a week from 5 weeks of age,
and mice were sacrificed at 10 weeks of age.

8

9 *In vitro* osteoclast differentiation.

For murine samples, FACS-sorted primary blood monocytes and synovial monocytes/macrophages (1 × 10⁴ cells per samples) were cultured with 10 ng/ml M-CSF in MEM containing 10% FCS. After 2 days, cells were cultured for 3 days in MEM containing 10 ng/ml M-CSF and 100 ng/ml RANKL unless otherwise noted. Murine TNF- α (315-01A; PeproTech), murine IL-6 (406-ML; R&D systems), and murine osteoprotegerin (459-MO; R&D systems) were added at the concentrations indicated in the figure legends. Nunclon Sphera plates

(174927; Thermo Fisher Scientific) were used for non-adherent conditions. Bone
 marrow OP-containing populations (BM-OPs) represent the
 CD45⁺CX₃CR1⁺Ly6C^{hi} bone marrow population with osteoclast precursor
 activity^{8,13}.

5 For human samples, FACS-sorted cells (2 × 10⁴ cells per samples) were 6 cultured with 30 ng/ml M-CSF in MEM containing 10% FCS for 2 days, followed 7 by incubation with 30 ng/ml M-CSF and 100 ng/ml RANKL for 9 days.

8

9 Sorting of mature osteoclasts from RepCell

10	To avoid cell damage during isolation of osteoclasts from plates, the
11	temperature-responsive cell cultureware, RepCell (CellSeed), was used.
12	Multiple CIA mice (CX ₃ CR1-EGFP/TRAP-tdTomato) were sacrificed to isolate 1
13	$\times~10^5$ R3 cells from inflamed knee and ankle joints. Sorted R3 cells were
14	incubated with 10 ng/ml M-CSF for 48 h, followed by incubation with 10 ng/ml
15	M-CSF and 100 ng/ml RANKL for 96 h to induce osteoclastogenesis. Cells were
16	gently collected after a 10 min incubation at 4°C and stained with Hoechst 33342

(1:1000). The multinucleated FSC^{hi}SSC^{hi}tdTomato⁺ cell population were gated
 and sorted by flow cytometry.

3

4 Bone resorption assay.

Primary blood monocytes, synovial macrophages, and BM-OPs were isolated 5 from CIA mice, sorted onto Osteo Assay Surface plates (Corning) coated with 6 inorganic crystalline calcium phosphate, and cultured with 100 ng/ml RANKL 7 8 and 10 ng/ml M-CSF for 6 days. After removing cells with sodium hypochlorite, resorption pits were photographed and analyzed using a BZ-X700 fluorescence 9 microscope (Keyence). 10 11 **Electroporation** 12 Bone marrow-derived macrophages were obtained from WT mice by culturing 13 bone marrow cells collected from the tibias and femurs of 8–10-week-old males. 14 Pelleted cells (1 × 10⁶ cells per sample) were suspended in 100 μ l of Mouse 15 Macrophage Nucleofector Solution (Lonza, VPA-1009) and we combined the 16

1	cell suspension with cytomegalovirus promoter (CMV)-T7-tagged FoxM1
2	plasmid (CMV-T7-FoxM1; a gift from Dr. Pradip Raychaudhuri) or mock plasmid.
3	The cell/DNA suspension was transferred into an Amaxa electrode cuvette and
4	electroporated in Amaxa Nucleofector Device II using program Y-001. Then,
5	the cells were cultured in MEM supplemented with 10 ng/ml M-CSF for 48 hours
6	for real-time PCR analyses. To analyze osteoclast differentiation, cells were
7	cultured for an additional 4 days in MEM containing 100 ng/ml RANKL and
8	M-CSF at the indicated concentrations.
9	

10 Statistical Analysis.

The results are shown as single data points in a scatter dot plot and as mean \pm SEM. Between group differences were determined using the two-tailed *t* test. One-way ANOVA with Bonferroni's post hoc test was used for comparisons among three or more groups. Associations were assessed using Pearson's correlation. Statistical analyses were performed using GraphPad Prism

(GraphPad Software). Statistical methods to predetermine sample size were not 1 applied. Animal and human sample sizes are indicated on scatter dot plots. 2 3 Data availability. 4 The data sets analyzed during the current study are available from the 5 6 corresponding author upon reasonable request. Access to raw RNA-seq data related to this study is available through the Gene Expression Omnibus (GEO) 7 8 (accession number: GSE 117149 and GSM 3712154 for single cell RNA-seq). 9 10 Jung, S. et al. Analysis of fractalkine receptor CX3CR1 function by targeted 11 46. deletion and green fluorescent protein reporter gene insertion. Mol. Cell. 12 Biol. 20, 4106–4114 (2000). 13 47. Kikuta, J. et al. Dynamic visualization of RANKL and Th17-mediated 14 osteoclast function. J. Clin. Invest. 123, 866-873 (2013). 15 48. Takeda, K. et al. Enhanced Th1 activity and development of chronic 16

1		enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.
2		Immunity 10 , 39–49 (1999).
3	49.	Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis.
4		<i>Nat. Protoc.</i> 2 , 1269–1275 (2007).
5	50.	Kamran, P. <i>et al.</i> Parabiosis in mice: a detailed protocol. <i>J. Vis. Exp.</i> 1–5
6		(2013). doi:10.3791/50556
7	51.	Kawamoto, T. Use of a new adhesive film for the preparation of
8		multi-purpose fresh-frozen sections from hard tissues, whole-animals,
9		insects and plants. Archives of Histology and Cytology 66, 123–143 (2003).
10	52.	Ishii, M., Kikuta, J., Shimazu, Y., Meier-Schellersheim, M. & Germain, R. N.
11		Chemorepulsion by blood S1P regulates osteoclast precursor mobilization
12		and bone remodeling in vivo. <i>J. Exp. Med.</i> 207 , 2793–2798 (2010).
12		